Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine
2023-02-01

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00442 JCO Precision Oncology no. 7 (2023) e2200442. Published online February 27, 2023. PMID: 36848609 Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine Melissa Lumish , MD1xMelissa LumishSearch for articles by this author; Jennifer Thackray , PharmD2xJennifer ThackraySearch for articles by this author; Richard Kinh Gian Do , MD, PhD3xRichard Kinh Gian DoSearch for articles by this author; Kelly E. Caudle, PharmD4xKelly E. CaudleSearch for articles by this author; Ursula Amstutz , MSc, PhD5xUrsula AmstutzSearch for articles by this author; Matthias Schwab , MD6,7,8,9xMatthias SchwabSearch for articles by this author; Robert B. Diasio , MD10xRobert B. DiasioSearch for articles by this author; William R. Jarnagin, MD11xWilliam R. JarnaginSearch for articles by this author; and Andrea Cercek , MD1xAndrea CercekSearch for articles by this author Show More 1Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY2Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY4Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital Memphis, TN5Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland6Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany7Department of Clinical Pharmacology, University Hospital, Tübingen, Germany8Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University Hospital, Tübingen, Germany9Cluster of Excellence iFIT (EXC 2180), “Image-Guided and Functionally Instructed Tumor Therapies,” University of Tuebingen, Tuebingen, Germany10Department of Molecular Pharmacology and Experimental Therapeutics and Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN11Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY https://doi.org/10.1200/PO.22.00442 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Melissa Lumish, Jennifer Thackray, Andrea CercekCollection and assembly of data: Melissa Lumish, William R. Jarnagin, Andrea CercekData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jennifer ThackrayEmployment: Equashield (I)Consulting or Advisory Role: Wolters Kluwer/LexicompRichard Kinh Gian DoHonoraria: ALK (I), Genentech (I)Consulting or Advisory Role: DBV Technologies (I), Bayer, GE HealthcarePatents, Royalties, Other Intellectual Property: UptoDate chapters on Food Allergy (I)Kelly E. CaudleEmployment: Horizon Therapeutics (I)Stock and Other Ownership Interests: Horizon Therapeutics (I)Ursula AmstutzHonoraria: Roche Sequencing SolutionsMatthias SchwabHonoraria: CED Service GmbH, Österreichische Apothekerkammer, Research Impact Fund Committee (RIF), Research Grant Council (RCG), Hong KongConsulting or Advisory Role: Agena BioscienceResearch Funding: Gilead Sciences (Inst), CORAT Therapeutics GmbH (Inst), Agena Bioscience (Inst), HepaRegeniX (Inst)Patents, Royalties, Other Intellectual Property: Gene expression signature for subtype and prognostic prediction of renal cell carcinoma (Inst)Other Relationship: Wolters Kluwer Health Inc, Thieme Medical Publishers, Genome MedicineAndrea CercekConsulting or Advisory Role: Bayer, GlaxoSmithKline, Incyte, Merck, Janssen, Seattle Genetics, G1 TherapeuticsResearch Funding: Seattle Genetics, Rgenix (Inst), GlaxoSmithKlineNo other potential conflicts of interest were reported.